Merck Reports Double-Digit Revenue and Earnings-Per-Share Growth for Third-Quarter 2007.

* Company Announces Third-Quarter 2007 Earnings Per Share (EPS) of $0.75, Excluding Restructuring Charges; Third-Quarter Reported EPS of $0.70

* Twelve Percent Revenue Growth Driven by Key Products SINGULAIR, JANUVIA, GARDASIL and VARIVAX

* Equity-Income Growth Driven by Strong Performance of VYTORIN and ZETIA

* ISENTRESS, Merck's First-in-Class HIV Integrase Inhibitor, Approved by U.S. Food and Drug Administration (FDA)

* Merck Raises Full-Year 2007 EPS Guidance and Now Anticipates EPS Range of $3.08 to $3.14, Excluding Restructuring Charges; Reported 2007 EPS Range of $2.87 to $2.93

WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. today announced third-quarter 2007 earnings per share of $0.75, excluding restructuring charges, and third-quarter reported EPS of $0.70. Worldwide sales were $6.1 billion for the quarter, an increase of 12 percent from the third quarter of 2006. Net income for the third quarter of 2007 was $1,525.5 million compared with $940.6 million in the third quarter of 2006. Net income and EPS for the third quarter of 2007 include the impact of an acquired research charge of $325 million or $0.15 per share related...

If you are already a vLex customer, Access Here